Kimberly D Tipton

US Patent:

20210222143, Jul 22, 2021

Filed:

Jan 3, 2020

Appl. No.:

16/734256

Inventors:

- South San Francisco CA, US
Christopher Thanos - Tiburon CA, US
Vanessa Soros - San Francisco CA, US
Mikhail Popkov - San Diego CA, US
Kimberly Tipton - Boston MA, US
Matthew John Traylor - Boulder CO, US
Eric Steven Furfine - Lincoln MA, US
Jeffrey Charles Way - Cambridge MA, US

International Classification:

C12N 9/72
C07K 14/765

Abstract:

Provided are u-PA polypeptides and fusion proteins containing the u-PA polypeptides. The u-PA polypeptides are modified to have altered activity and/or specificity so that they cleave a complement protein, such as complement protein C3, to thereby inhibit complement activation. The modified u-PA polypeptides and fusion proteins that inhibit complement activation can be used for treatment of diseases and conditions that are mediated by complement activation, or in which complement activation plays a role. These disorders include ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, diabetic retinopathies, age-related macular degeneration, transplanted organ rejection, inflammatory diseases and diseases with an inflammatory component.